1.A Non-rigid Medical Image Registration Algorithm Based on Modally Controlled Free Form Deformation
Yongming ZHAO ; Su ZHANG ; Zhao ZHANG ; Yazhu CHEN
Space Medicine & Medical Engineering 2005;18(4):240-245
Objective To register pre-operative MRI/CT images with intra-operative ultrasound images based on vessels visible in both of the modalities. Method A non-rigid registration method of multimodal medical images based on Free Form Deformation(FFD) was proposed. When the images were aligned, the centerline points of the vessels in one image aligned with the intensity ridge points in the other image. Rigid transformation was adopted in global registration while local deformation was described by a Free Form Deformation based on a modally controlled B-spline. The method applied an optimization strategy combining the genetic algorithm with the conjugated gradients algorithm to minimize the objective function. Result Two experiments were designed on phantom and clinical data to evaluate the method. The results demonstrated that the registration method was consistent accurate. The average standard deviation of the final transformation parameters was sub-voxel, sub-millimeter, and within 0.010 radians. Conclusion The results show that the method has good registration accuracy and convergence rate. It can be applied efficiently in the ultrasound-image-guided surgery system.
2.Activation of group I metabotropic glutamate receptors in rat striatum induces contralateral rotation
Fang YUAN ; Zhongcheng WANG ; Lixin XU ; Tianyou WANG ; Yazhu ZHANG
Chinese Journal of Pathophysiology 1989;0(05):-
AIM: To study the subtype of metabotropic glutamate receptors (mGluRs) which induce contralateral rotations of rats after mGluRs activation. METHODS: Turning movement was measured at 6 h after agonist or antagonist of mGluRs was microinjected into rat striatum. RESULTS: tACPD, an agonist of mGluRs, at 500 nmol and 1 000 nmol induced contralateral rotations of rats. L-AP 3, MCPG and dantrolene attenuated the turning effect of tACPD. DHPG, a selective agonist of group I mGluRs, mimicked the effect of tACPD. The effect of DHPG was blocked by MCPG, LY367385 (antagonist of mGluR 1) and MPEP (antagonist of mGluR 5), and abolished by pretreatment with reserpine (5 mg/kg). CONCLUSION: These results indicated the activation of group I mGluRs in rat striatum induced turning effect, which may be associated with the mobilization of intracellular Ca 2+ stores and dependant on the existence of dopamine.
3.A systematic review for Qili Qiangxin Capsule for chronic heart failure
Chunxiang LIU ; Jingyuan MAO ; Xianliang WANG ; Yazhu HOU ; Chuan ZHANG
Chinese Traditional Patent Medicine 1992;0(04):-
AIM: To evaluate the clinical efficacy and safety of Qili Qiangxin Capsule(Radix Astragali,Radix Aconiti lateralis praeparata,Radix et Rhizoma Salviae miltiorrhizae,Radix et Rhizoma Ginseng,Semen Lepidii,Semen Descurainiae,Flos Carthami,Pericarpium Citri reticulatae,Rhizoma Alismatis,Cortex Periplocae,Rhizoma Polygonati odorati,Ramulus Cinnamomi) with chronic heart failure(CHF).METHODS: Seven randomized controlled trials were reviewed.RESULTS: The meta-analysis indicated that the treatment group of Qili Qiangxin Capsule could decrease the cardiac functional grading of NYHA with 1.21 of the relative risk,and 95% confidence interval(CI) from 1.08 to 1.36;increase 6 minute walking distance with the weighted mean difference(WMD) was 37.39,and 95% confidence interval was from 22.58 to 52.20;raise left ventricular ejection fraction(WMD = 3.97[2.09,5.85]),decrease the left ventricular end-diastolic diameter(WMD = 2.81[1.41,4.22]),lower the level of B-type natriuretic peptide(WMD = 118.00[4.44,231.56]) and N-terminal pro-brain natriuretic peptide(WMD = 476.90[371.26,582.54]) in blood plasma and drop the score of Minnesota living with heart failure questionnaire(WMD =8.00[3.48,12.52]),but Qili Qiangxin Capsule for reduction in left ventricular end-diastolic volume,left ventricular end-systolic volume,heart rate and blood pressure also need to be confirmed.Besides,individual ca-ses occurred adverse reactions like dry cough,epigastric discomfort,gastric distention.However,It could be tolerated and hadn't significant statistical difference with comparison to control group.CONCLUSION: Qili Qiangxin Capsule is effective and safe for the patients of chronic heart failure in improving the heart function and living quality.
4.Improved Determination Method for Free Salicylic Acid in Paracetamol, Caffeine and Aspirin Powder
Wanping LI ; Li WAN ; Hua ZHANG ; Yazhu MAI
China Pharmacist 2017;20(8):1494-1495,1507
Objective: To establish a determination method for free salicylic acid in paracetamol, caffeine and aspirin powder by HPLC.Methods: The column was Welch Ultimate(C) C 18 (250 mm× 4.6 mm , 5 μm), the mobile phase was acetonitrile-tetrahydrofuran-glacial acetic acid-water(22∶5∶5∶68), the detection wavelength was 303 nm, and the flow was 1.0 ml·min-1.Results: The linear range of hydrochloride was 1.500-75.000 μg·ml-1 (r=0.999 9), the average recovery was 99.12% with RSD of 0.75% (n =9),and the detection limit was 1.5 ng (S/N =3).Conclusion: The method is simple, the result is accurate with higher sensitivity and the better reproducibility, which can be used for the determination of free salicylic acid in paracetamol, caffeine and aspirin powder.
5.Clinical epidemiology survey of the traditional Chinese medicine etiology and syndrome differentiation of coronary artery disease: study protocol of a multicenter trial.
Yingfei BI ; Jingyuan MAO ; Xianliang WANG ; Yazhu HOU ; Yizhu LU ; Boli ZHANG
Journal of Integrative Medicine 2012;10(6):619-27
BACKGROUD: Coronary artery disease (CAD), a common disease with high incidence and mortality rate, has seriously threatened the health and life of the public. Traditional Chinese medicine (TCM) has an important role in the prevention and treatment of this disease. Through clinical epidemiological survey, a deeper understanding of TCM etiology and syndrome characteristics in CAD would further improve clinical efficacy in the treatment of this disease.
7.Development and application of the phased HIFU system software.
Shengfa ZHANG ; Guofeng SHEN ; Xiang JI ; Dehui LI ; Hongbin CAI ; Yazhu CHEN
Chinese Journal of Medical Instrumentation 2010;34(4):255-257
This paper introduces HIFU system software based on a phased-array HIFU device. Combined with the database and computer graphics technology, this HIFU system software can be used to develop the therapy planning semi-automatically, implement the pilot project efficiently and accelerate the clinical studies.
Computer Graphics
;
High-Intensity Focused Ultrasound Ablation
;
methods
;
Software
;
Software Design
8.Efficacy analysis of imatinib combined with chemotherapy for treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
Jing WANG ; Xin WEI ; Yazhu WANG ; Xia LI ; Lijun ZHANG
Journal of Leukemia & Lymphoma 2019;28(1):30-33
Objective To investigate the clinical effects of imatinib combined with chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Methods A total of 35 newly diagnosed Ph+ ALL patients from June 2012 to January 2016 in the First Hospital of China Medical University were enrolled. The patients were divided into 21 cases (combined chemotherapy group) and 14 cases (chemotherapy alone group). There were 4 patients in combined chemotherapy group who underwent hematopoietic stem cell transplantation (HSCT) after the first complete remission (CR). The parameters including blood routine, bone marrow morphology, immunoassay, chromosome and fusion genes were detected regularly for efficacy assessment. Results CR rate after the first induction therapy was 76% (16/21) in combined chemotherapy group and 36% (5/14) in the chemotherapy alone group, and there was a significant difference of both groups (χ 2 = 5.734, P = 0.033). The median overall survival (OS) time for patients in combined chemotherapy group and chemotherapy alone group were 14 months (2-18 months) and 5 months (0.33-10 months) respectively (U = 12.0, P = 0.007). And the median disease-free survival (DFS) time were 8 months (0-15 months) and 2 months (0-6 months), respectively (U = 12.5, P = 0.007). The median OS and DFS time for transplant patients were 26 months (22-39 months) and 22 months (17-36 months) respectively. Conclusions Imatinib combined chemotherapy can increase CR rate, DFS and OS time for Ph+ ALL patients during the induction therapy, which can gain more chance to receive HSCT. The patients who could receive HSCT as soon as possible after CR1 could get longer survival time.
9.Correlation study of gamma-glutamyl transferase/high density lipoprotein cholesterol ratio,neutrophil/lymphocyte ratio and coronary heart disease
Yazhu WANG ; Yunfei GUO ; Ying ZHANG ; Weichao SHAN ; Wanglexian SUN ; Fei SHI ; Haoran ZHANG ; Wenping XUE
Clinical Medicine of China 2021;37(6):488-495
Objective:To investigate the correlation between gamma-glutamyl transferase/high-density lipoprotein cholesterol ratio (GHR), neutrophil/lymphocyte ratio (NLR) and coronary heart disease (CHD), and evaluated its pathogenic risk and predictive value for CHD.Methods:A total of 694 patients admitted to our hospital from December 2017 to December 2018 for suspected CHD and coronary angiography were selected. According to the results of coronary angiography,the patients were divided into CHD group ( n=527) and non-CHD group ( n=167). The clinical data of all patients were recorded. Gamma-glutamyl transferase (GGT), high-density lipoprotein cholesterol (HDL-C) and other biochemical indicators were recorded. Neutrophils, lymphocyte count and other hematological indicators were recorded. GHR, NLR and Gensini scores of the patients were calculated. Clinical data and GHR, NLR and other indicators were compared between the two groups. Receiver operating characteristic curve (ROC) was used to evaluate the predictive value of GHR, NLR in CHD, and to determine the optimal cut-off value; Logstic regression analysis was used to investigate the risk factors of CHD.Spearman correlation analysis was used to analyze the correlation between serum OPN, OPG and Gensini score in patients with CHD. Results:The GHR and NLR were 32.59(21.05, 48.24) and 3.53(2.18, 8.46) significantly higher in the CHD group than in the non-CHD group 16.56(10.07, 25.21) and 2.20(1.45, 3.28) respectively, with statistically significant differences ( Z=11.094, 9.055, P<0.05). ROC curve analysis showed that the AUC of NLR and MLR in diagnosing CHD was 0.785 and 0.732( P<0.05). When the critical values of GHR and NLR respectively were 19.805 and 2.678, respectively, the diagnostic efficiency of CHD was the highest, and the sensitivity and specificity were 79.30%, 62.90% and 63.80%, 68.30%, and the AUC of GGT in diagnosing CHD was 0.628. When the critical value was 19.500, the sensitivity and specificity were 80.50% and 39.50%, respectively,the AUC of GHR was greater than that of GGT ( Z=12.973, P<0.05). Multivariate Logistic regression analysis showed that Smoking ( OR=2.887, 95% CI:1.850-4.505, P<0.05), hypertension ( OR=2.009, 95% CI: 1.311-3.080, P<0.05), fasting plasma glucose ( OR=1.109, 95% CI:1.034-1.189, P<0.05), age ≥60 years ( OR=1.567, 95% CI:1.179-2.415, P<0.05), NLR ≥2.687 ( OR=3.152, 95% CI:2.066-4.808, P<0.05) and GHR ≥19.805 ( OR=4.768, 95% CI:3.131-7.262, P<0.05) was an independent risk factor for CHD. After gradually adjustment for risk factors such as smoking, hypertensive, fasting plasma glucose, age ≥60 years and NLR ≥2.687, GHR ≥19.805 was still an independent risk factor for coronary heart disease(OR and 95% CI were 4.620 (3.049-7.000), 4.768 (3.131-7.262), 6.567 (4.408-9.810), 4.768 (3.131-7.262), 4.768 (3.131-7.262), respectively; all P<0.001). Spearman correlation analysis showed that GHR and NLR were positively correlated with Gensini score ( r=0.312, 0.394; all P<0.05). Conclusion:GHR and NLR were positively correlated with the severity of coronary artery disease, which is of significance in the diagnosis of coronary heart disease. NLR ≥2.687 and GHR ≥19.805 were independent risk factors for CHD. GHR was superior to GGT and HDL-C alone in the diagnosis of CHD,and has certain clinical application value
10.Correlation between serum osteopontin and osteopontin and type 2 diabetes mellitus with coronary heart disease
Yazhu WANG ; Yunfei GUO ; Chao LIU ; Weichao SHAN ; Wenfeng WANG ; Aiwen ZHANG ; Wanglexian SUN ; Ying ZHANG
Clinical Medicine of China 2022;38(1):47-52
Objective:To study the relationship between serum osteopontin and osteopontin and type 2 diabetes mellitus (T2DM) complicated with coronary heart disease, and to evaluate the correlation between the levels of serum osteopontin and osteopontin with the severity of coronary artery lesions in T2DM patients.Methods:A total of 100 T2DM patients who were suspected to have stable coronary heart disease and underwent coronary angiography from November 2019 to December 2020 were selected from the Affiliated Hospital of Chengde Medical College, according to coronary angiography results, 60 patients with confirmed coronary heart disease were classified as the case group and 40 patients with non-coronary heart disease were classified as the control group for retrospective analysis. The clinical data and biochemical indicators of all patients were recorded, and Gensini score was calculated. The concentration of osteopontin and osteopontin in serum was quantitatively determined by double-antibody enzyme linked immunosorbent assay method. Independent sample t-test was used to compare the mean of normal distribution measurement data between the two groups. The non normal distribution data are represented by M ( Q1, Q3), and Mann Whitney U test is used for comparison between groups. Composition comparison between count data groups χ 2 inspection. Spearman correlation analysis was used to analyze the correlation between serum osteopontin and osteopontin and Gensini score in patients with T2DM. Results:Univariate analysis showed that serum osteopontin and osteopontin were (13.076(8.433, 23.552) μg/L) and (0.437(0.300, 0.630) μg/L) significantly higher in the case group than in the control group (6.367(4.605, 9.048) μg/L) and (0.299(0.196, 0.399) μg/L) respectively, with statistically significant differences ( Z=5.12, 3.28, all P<0.001). Multi-factor logistic regression analysis showed that osteoprotegerin ( OR=2.887, 95% CI:1.850-8.515, P=0.024) and osteopontin ( OR=13.109, 95%CI: 2.557-67.204, P=0.002) were associated with T2DM combined with coronary heart disease, and the risk of T2DM combined with coronary heart disease increased with higher levels of osteoprotegerin and osteopontin. Spearman correlation analysis showed that serum osteopontin and osteoprotegerin were positively correlated with Gensini score in T2DM patients ( r=0.591, 0.467; all P<0.05). Conclusion:Serum osteopontin and osteoprotegerin are associated with T2DM combined with coronary heart disease, and high serum osteopontin and osteoprotegerin are risk factors for T2DM combined with coronary heart disease; serum osteopontin and osteoprotegerin are positively correlated with the degree of coronary artery disease in T2DM patients.